Overdosing or abuse of this drug can lead to health complications such as oily skin, acne, exacerbation of male pattern baldness, growth of body/facial hair, deepening of the voice, and menstrual irregularities. The use of Mesterolone is not recommended to patients with carcinoma of the prostate or those who are undergoing androgen therapy of any kind, including the use of Proviron. In case a dose of this drug has been missed and it is almost time for the next dose, the first dose should be ignored and the next dose should be taken at the designated time. Under no circumstances, two doses of the drug should be taken together for the dose that was missed. Medical advice should be sought without any delay and use of Proviron should be stopped immediately if side effects such as pain in liver area, headache, loss of appetite, depression, unexplained weight loss, aggression, symptoms of an enlarged prostate (change in urination), acne, or hirsutism are experienced.
The most common daily dose of Anapolon is 100mg, but even at that dosage side-effects like water-retention, elevated blood pressure, acne, hair loss, blood clotting changes, gynocomastia, liver toxicity and mood swings are very often reported. Using aromatase inhibitors to control estrogen aromatization will be ineffective as this drug does not directly convert into estrogen. It was suggested that oxymetholone can activate the estrogen receptor, similar to, but more profoundly than the estrogenic androgen methandriol. Supplements like Milk Thistle can be taken to help keep liver enzyme levels between safe ranges.
In one small scale clinical trial of depressed patients, an improvement of symptoms which included anxiety, lack of drive and desire was observed.  In patients with dysthymia , unipolar , and bipolar depression significant improvement was observed.  In this series of studies, mesterolone lead to a significant decrease in luteinizing hormone and testosterone levels.  In another study, 100 mg mesterolone cipionate was administered twice monthly.  With regards to plasma testosterone levels, there was no difference between the treated versus untreated group, and baseline luteinizing hormone levels were minimally affected.